Among participants allocated to rosuvastatin , @ fractures were confirmed , compared with @ among those allocated to placebo , such that the incidence of fracture in the rosuvastatin and placebo groups was @ and @ per @ person-years , respectively ( adjusted HR , @ -LSB- @ % CI , @-@ @ -RSB- ; P = @ ) .